New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:33 EDTCVMCEL-SCI reports continued increase in patient enrollment in Phase III trial
CEL-SCI Corporation announced that during the month of May the company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014. So far, a total of 197 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:17 EDTCVMCEL-SCI reports enrolling 25 patients in February for Multikine study
CEL-SCI announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its phase III head and neck cancer trial for its investigational immunotherapy Multikine -- Leukocyte Interleukin, Injection. A total of 377 patients have been enrolled in study in head and neck cancer as of February 28. “During the month of February we also received clearance in the Philippines, Malaysia and Belarus to begin patient enrollment in those countries. This is expected to result in an even higher number of patients being enrolled in the study in March,” stated CEL-SCI CEO Geert Kersten. The goal is to enroll a total of 880 patients through approximately 100 clinical centers in about 25 countries by the end of 2015.
March 2, 2015
08:46 EDTCVMCEL-SCI cleared to enroll patients in trial in Belarus
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use